The Global Chronic Obstructive Pulmonary Disease (COPD) Market is expected to register a CAGR of 4.5% to touch USD 25.7 Billion from 2020 TO 2027. COPD is a progressive and long-term lung disease which involves thickening and inflammation of the airways. The airways over time become increasingly blocked, thus making it difficult to breathe. Chronic Obstructive Pulmonary Disease comprises of two chronic conditions namely chronic bronchitis and emphysema. The former causes persistent cough combined with mucus and inflammation of airways and the latter is caused through a damage in the lung tissue resulting in shortness of breath. Along with air pollution and tobacco smoke, the other factors that can cause COPD directly or indirectly include dietary factors, poor socio-economic status, impaired lung growth, chronic asthma, poor nutritional status, respiratory infections, smoke from burning of biomass, exposure to passive smoking or second-hand smoking, outdoor pollution and occupational exposure. Besides, there are other factors such as rare genetic disorders and old age that can contribute to the prevalence of chronic obstructive pulmonary disease.

There are abundant factors that is propelling the growth of the chronic obstructive pulmonary disease market. These factors as per the Market Research Future (MRFR) report include unhealthy lifestyle, environmental pollution, growing number of smokers, prevalence of asthma, technological advancements, increase in geriatric population, change in lifestyle, personalization of medicine, healthcare awareness, high disposable income, economic development especially in emerging economies and introduction of new technology.

Request Free Sample Copy at:

Market Segmentation

MRFR report offers a broad segmental analysis of the chronic obstructive pulmonary disease market on the basis of medicines, treatments and types.

Based on medicines, it is segmented into bronchodilators, antibiotics, theophylline, phosphodiesterase-4 inhibitors, oral steroids, inhaled steroids and combination inhalers.

Based on treatment, the chronic obstructive pulmonary disease market is segmented into bullectomy, lung transplant, oxygen therapy and others.

Based on types, it is segmented into emphysema and chronic bronchitis.

Regional Analysis

By region, the chronic obstructive pulmonary disease market covers growth opportunities and latest trends across Americas, Asia Pacific, Europe and Middle East and Africa. Of these, North America will lead the market during the forecast period owing to increasing pool of investment and advanced medical facilities. The US and Canada are the key contributors here. The chronic obstructive pulmonary disease market in Europe will have the second major share with developing nations such as Spain, the United Kingdom, Spain, France, Italy and Germany being the key contributors. The chronic obstructive pulmonary disease market in the APAC region is predicted to have an outstanding growth owing to improving medical infrastructure and high population density in countries across the region. The market here is predicted to grow at the fastest pace wherein countries such as South Korea, India, China, Japan, Australia and others are significantly contributing to the growth of this region in its entirety. On the other hand, the chronic obstructive pulmonary disease market in the Middle East and Africa is projected to have a meagre growth during the forecast period owing to minimal investment made in the healthcare industry and limited and poor infrastructure. However, the increasing prevalence of smoking hookah in Gulf nations boosted the percentage of COPD in this region.

Key Players

Leading players profiled in the chronic obstructive pulmonary disease market include Pfizer Inc (USA), Novartis AG (Switzerland), Merck (USA), GSK (UK), F. Hoffmann-La Roche Ltd (Switzerland), Dr. Reddy’s Laboratories Ltd (India), AstraZeneca (UK), Abbott (USA) and others.

April 2019- Spry Health’s latest clinical-grade wearable has received clearance from the FDA. The Loop wristband system from FierceMedTech can remotely measure pulse oximetry, respiration and heart rate and is specially designed for those with COPD (chronic obstructive pulmonary disease). This wearable is simple to use and does not need any data or input from patients as well as does not need an app or smartphone. The wristband appears as a general activity tracker or consumer-oriented fitness tracker and above all is comfortable to wear throughout the day. Using optical sensors, this wristband will aid physicians in spotting the early symptoms of COPD before exacerbations and obvious symptoms occur.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

Source link